Novavax | NVAX - Current Assets


Novavax reported $978.28M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Adma Biologics USD 466.51M 63.86M Dec/2025
Agenus USD 133.44M 514K Dec/2025
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Cassava Sciences USD 97.71M 11.2M Dec/2025
Geron USD 520.27M 2.07M Dec/2025
GlaxoSmithKline GBP 17.76B 251M Mar/2026
MannKind USD 291.58M 67.26M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.77B 774M Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 42.82B 76M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025